Table 6. Association between rs4693608 SNP and Time of Neutrophil and Platelet Reconstitution after HSCT.

Group of analysis	Genotype	n	Comparison of carriers	Neutrophils		Platelets
				Z value	P value	Z value	P value
Patients	AA	124	AA to GG	1.29	NS	1.0	NS
	AG	227	AA to AG + GG	−1.56	.059	−1.53	0.063
	GG	98	GG to AA + AG	0.56	NS	0.26	NS
Donors	AA	110	AA to GG	−0.49	NS	−1.31	NS
	AG	207	AA to AG + GG	−0.16	NS	1.15	NS
	GG	81	GG to AA + AG	−0.91	NS	−1.0	NS
Discrepancy	D1	54	D1 to D2	−1.66	0.049	−1.67	0.047
	D2	120	D1 to D3	−1.84	0.033	−1.32	NS
	D3	235	D2 to D3	0.27	NS	−0.29	NS
Differences in heparanase levels	N1	89	N1 to N2	−2.17	0.015	−2.04	0.021
	N2	191	N1 to N3	−2.7	0.003	−1.9	0.029
	N3	104	N2 to N3	0.75	NS	0.2	NS

Discrepancy according to the risk of aGVHD development: D1, AA-AG and AA-GG recipient-donor pairs; D2, AG-AG, AG-AA, AG-GG, and AA-AA recipient-donor pairs; and D3, GG-GG, GG-AA, and GG-AG recipient-donor pairs. Three newly designed recipient-donor pair groups, according to their presumable differences in heparanase expression: N1, AA-AG, AA-GG, and AG-GG recipient-donor pairs (recipient heparanase expression is presumably higher compared with the donor); N2, AA-AA, AG-AG, and GG-GG recipient-donor pairs (the same HPSE gene expression levels); and N3, GG-AG, GG-AA, and AG-AA recipient-donor pairs (low heparanase expression in the patients relative to high expression level in the donors). Significant deviations (P<0.05) are in boldface.